Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ONCO.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-1.01
vs -5.23
Q1.23
N/A
-0.79
vs -1.31
Q2.23
N/A
-0.62
vs -0.79
Q3.23
N/A
-0.45
vs -1.00
Q4.23
N/A
-0.90
vs -1.01
Q1.24
N/A
-0.53
vs -0.79
Q2.24
N/A
-0.48
vs -0.62
Q3.24
N/A
-0.29
vs -0.45
Q4.24
N/A
-0.39
vs -0.90
Q1.25
N/A
-0.29
vs -0.53
Sales Growth
YoY
Current
Estimates
Q2.23
+197%
26M vs 8.8M
Q3.23
+393%
2.8M vs -958000
Q4.23
+853%
5.3M vs 560K
Q1.24
+351%
5.1M vs 1.1M
Q2.24
-69%
8.2M vs 26M
Q3.24
+203%
8.5M vs 2.8M
Q4.24
+86%
9.9M vs 5.3M
Q1.25
+162%
13.3M vs 5.1M
Q2.25
+207%
25M vs 8.2M
Q3.25
+276%
32M vs 8.5M
Return on Equity
QoQ
Q2.23
-32%
-0.32
vs -0.31
Q3.23
-30%
-0.30
vs -0.32
Q4.23
-143%
-1.43
vs -0.30
Q1.24
+803%
8.03
vs -1.43
Q2.24
-38%
-0.38
vs 8.03
Q3.24
-44%
-0.44
vs -0.38
Q4.24
-154%
-1.54
vs -0.44
Q1.25
+1038%
10.38
vs -1.54
Institutionnal Ownership
Quote Panel
Key Metrics
Forecast
1598%2026-Revenue
-55%2026-EPS
-126%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
ONCO.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
STO
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.93Â ( -20.31%)
Relative Strenght
Volume Buzz
1029%
Earning Acce
No
Dist 52w H.
25%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ONCO.ST compares to sector?